[International study on testicular cancer: EORTC 30983: randomized phase II/III study of Taxol-BEP versus BEP in patients with Intermediate Prognosis Germ Cell Cancer].
Rexer
Frau H
FH
Geschäftsstelle der AUO. AUO@MeckEvidence.de
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D038622:Internationality; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000453:epidemiology*; D017239:Paclitaxel / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D016896:Treatment Outcome
D001761:Bleomycin; D005047:Etoposide; D017239:Paclitaxel; D002945:Cisplatin